Crockett Julie C, Schütze Norbert, Tosh Denise, Jatzke Susanne, Duthie Angela, Jakob Franz, Rogers Michael J
Bone Research Group, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom.
Endocrinology. 2007 Dec;148(12):5761-8. doi: 10.1210/en.2007-0473. Epub 2007 Sep 6.
Cysteine-rich protein 61 (CYR61/CCN1) belongs to the family of CCN matricellular proteins. Most of the known effects of CCN proteins appear to be due to binding to extracellular growth factors or integrins, including alpha(v)beta(3) and alpha(v)beta(5). Although CYR61 can stimulate osteoblast differentiation, until now the effect of CYR61 on osteoclasts was unknown. We demonstrate that recombinant human CYR61 inhibits the formation of multinucleated, alpha(v)beta(3)-positive, or tartrate-resistant acid phosphatase-positive human, mouse, and rabbit osteoclasts in vitro. CYR61 markedly reduced the expression of the osteoclast phenotypic markers tartrate-resistant acid phosphatase, matrix metalloproteinase-9, calcitonin receptor, and cathepsin K. However, CYR61 did not affect the formation of multinucleated osteoclasts when added to osteoclast precursors prior to fusion or affect the number or resorptive activity of osteoclasts cultured on dentine discs, indicating that CYR61 affects early osteoclast precursors but not mature osteoclasts. CYR61 did not affect receptor activator of nuclear factor-kappaB (RANK) ligand-induced phosphorylation of p38 or ERK1/2 in human macrophages and did not affect RANK ligand-induced activation of nuclear factor-kappaB, indicating that CYR61 does not appear to inhibit osteoclastogenesis by affecting RANK signaling. Furthermore, a mutant form of CYR61 defective in binding to alpha(v)beta(3) also inhibited osteoclastogenesis, and CYR61 inhibited osteoclastogenesis similarly in cultures of mouse wild-type or beta(5)(-/-) macrophages. Thus, CYR61 does not appear to inhibit osteoclast formation by interacting with alpha(v)beta(3) or alpha(v)beta(5). These observations demonstrate that CYR61 is a hitherto unrecognized inhibitor of osteoclast formation, although the exact mechanism of inhibition remains to be determined. Given that CYR61 also stimulates osteoblasts, CYR61 could represent an important bifunctional local regulator of bone remodeling.
富含半胱氨酸的蛋白61(CYR61/CCN1)属于CCN基质细胞蛋白家族。CCN蛋白的大多数已知作用似乎是由于其与细胞外生长因子或整合素结合,包括α(v)β(3)和α(v)β(5)。尽管CYR61可以刺激成骨细胞分化,但直到现在CYR61对破骨细胞的作用仍不清楚。我们证明,重组人CYR61在体外可抑制人、小鼠和兔多核、α(v)β(3)阳性或抗酒石酸酸性磷酸酶阳性破骨细胞的形成。CYR61显著降低了破骨细胞表型标志物抗酒石酸酸性磷酸酶、基质金属蛋白酶-9、降钙素受体和组织蛋白酶K的表达。然而,当在融合前添加到破骨细胞前体中时,CYR61并不影响多核破骨细胞的形成,也不影响在牙本质盘上培养的破骨细胞的数量或吸收活性,这表明CYR61影响早期破骨细胞前体,但不影响成熟破骨细胞。CYR61不影响核因子-κB受体激活剂(RANK)配体诱导的人巨噬细胞中p38或ERK1/2的磷酸化,也不影响RANK配体诱导的核因子-κB激活,这表明CYR61似乎不是通过影响RANK信号来抑制破骨细胞生成。此外,一种与α(v)β(3)结合缺陷的CYR61突变体形式也抑制破骨细胞生成,并且CYR61在小鼠野生型或β(5)(-/-)巨噬细胞培养物中同样抑制破骨细胞生成。因此,CYR61似乎不是通过与α(v)β(3)或α(v)β(5)相互作用来抑制破骨细胞形成。这些观察结果表明,CYR61是一种迄今未被认识的破骨细胞形成抑制剂,尽管确切的抑制机制仍有待确定。鉴于CYR61也能刺激成骨细胞,CYR61可能是骨重塑的一种重要的双功能局部调节因子。